摘要
目的 :研究吉西他滨 (健择 ,GEM)与顺铂 (DDP)联合化疗方案治疗非小细胞肺癌 (NSCLC)的临床疗效、生存期及毒副反应。方法 :入选病人均为Ⅲ、Ⅳ期非小细胞肺癌。GEM 10 0 0mg/m2 d1,8,15 ,顺铂 10 0mg/m2 d1,2 8d为 1个疗程。结果 :16例可评价病人 ,总有效率 5 6 2 5 % (均为部分缓解 )。主要毒副反应为血液学毒性 ,Ⅲ—Ⅳ度血色素降低周期数占 2 6 0 % ,粒细胞减少周期数占 2 5 4% ,血小板减少周期数占32 7%。非血液学毒性轻微均可耐受。因毒性反应而延期化疗者仅 10 9% ,生存质量改善 ,Karnofsky计分增加者占 43 7% (7例 / 16例 ) ,中位缓解期 8月 ,中位生存期因时间尚短未能统计出。结论 :GEM与DDP联合化疗方案治疗NSCLC有较好疗效 ,耐受性较好 。
Purpose:To study the clinical activity, survival and toxicity of a new combination of chemotherapy with gemcitabine and cisplatin. Methods:Patients with stages Ⅲ and Ⅳ non small cell lung cancer (NSCLC) were included. Gemcitabine was administered on d 1,8 and 15 at a dose of 1?000 ?mg/m 2 and cisplatin at a dose of 100 mg/m 2 on d?1. The chemotherapy was repeated every 28 days. Results:Sixteen patients were evaluable for the response. the overall respone rate was 56.25% (partial response). The main toxicity was hematological:cycles of hemoglobin, neutropenia andthrombocytopenia of WHO grade Ⅲ—Ⅳ was 26.0%, 25.4% and 32.7%, respectively. The non hematological toxicity was mild and tolerable. Only in 10.9% of the patients was chemotherapy delayed due to drug toxicity. Quality of life of the patients was improved (there were 7 patients with Karnofsky score increased in 16 patients). Median remission duration was 8 months, and median survival time was not available. Conclusions:This regimen of gemcitabline and cisplatin is effective and well tolerated in the treatment of advanced NSCLC. So it is worth to be further studied.
出处
《中国癌症杂志》
CAS
CSCD
2000年第1期75-77,80,共4页
China Oncology
